Wedbush Reiterates Buy Rating for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “buy” rating reaffirmed by analysts at Wedbush in a research report issued on Tuesday, RTT News reports. They presently have a $79.00 price target on the biotechnology company’s stock. Wedbush’s target price suggests a potential upside of 267.78% from the stock’s previous close.

AIMT has been the topic of several other research reports. Zacks Investment Research raised Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Thursday, June 13th. BidaskClub raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $46.43.

Shares of NASDAQ:AIMT opened at $21.48 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. The company has a fifty day moving average of $20.15. Aimmune Therapeutics has a 52-week low of $19.25 and a 52-week high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. As a group, equities analysts expect that Aimmune Therapeutics will post -3.77 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Aimmune Therapeutics by 30.3% in the 1st quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock valued at $61,117,000 after purchasing an additional 635,362 shares during the last quarter. Eagle Asset Management Inc. lifted its stake in Aimmune Therapeutics by 0.8% during the 1st quarter. Eagle Asset Management Inc. now owns 1,326,933 shares of the biotechnology company’s stock worth $29,656,000 after acquiring an additional 10,579 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Aimmune Therapeutics by 15.3% during the 1st quarter. Victory Capital Management Inc. now owns 1,095,121 shares of the biotechnology company’s stock worth $24,476,000 after acquiring an additional 145,060 shares in the last quarter. Emerald Advisers LLC lifted its stake in Aimmune Therapeutics by 15.0% during the 1st quarter. Emerald Advisers LLC now owns 852,991 shares of the biotechnology company’s stock worth $19,064,000 after acquiring an additional 111,245 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its stake in Aimmune Therapeutics by 19.7% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 776,943 shares of the biotechnology company’s stock worth $17,365,000 after acquiring an additional 128,014 shares in the last quarter. 76.12% of the stock is currently owned by institutional investors and hedge funds.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: Why Invest in Dividend Achievers?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.